# Safety and Efficacy Evaluation of Decitabine With R-GDP

> **NCT03535753** · PHASE1 · UNKNOWN · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- NHL

## Interventions

- **DRUG:** Decitabine and R-GDP

## Key facts

- **NCT ID:** NCT03535753
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535753, "Safety and Efficacy Evaluation of Decitabine With R-GDP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03535753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*